CClinicalTrials.gg
CompletedNCT07179224Updated Mar 30, 2026

EEG Changes After rTMS Stimulation

An interventional study of Treatment with EXOMIND (BTL-699-2) in Brain Electrical Reactivity to BTL-699-2 Stimulation, sponsored by BTL Industries Ltd.. Completed at 1 site in Czechia. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by BTL Industries Ltd. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to explore the brain's electrical reactivity, monitored using EEG, following the EXOMIND (BTL-699-2) stimulation across various stimulation locations. The main question it aims to answer is:

What is the brain's cortical electrical reactivity, monitored using EEG, following the EXOMIND (BTL-699-2) stimulation across various stimulation locations?

Participants will be asked to:

  • Undergo 1 treatment visit
  • Undergo electroencephalography (EEG) measurements
  • Complete Therapy Comfort Questionnaires
Read the detailed description

This is a non-randomized, prospective, single-center, single-arm, open-label, interventional study. All participants will be treated with the EXOMIND (BTL-699-2) device.

Before the first stimulation, a resting EEG recording will be performed for 3 minutes with the subjects' eyes closed and 3 minutes with the subjects' eyes open.

The treatment administration phase consists of one (1) treatment visit. The intensity will be carefully adjusted based on subject feedback, but it should not exceed 70% of the motor threshold.

EEG measurements will be conducted, and the Therapy Comfort Questionnaire will be administered during the treatment visit.

The treatment area will be examined for possible adverse events after the stimulation and during both follow-up visits.

The safety follow-up visits will be 2 weeks (± 2 days) and 1 month (± 5 days) after the treatment visit.

After completing the final follow-up visit (1 month after the treatment visit), the patient's participation in the study will be considered complete. The estimated duration of participation, from the initial visit to the final follow-up, is approximately 2 months.

02

Conditions studied

  • Brain Electrical Reactivity to BTL-699-2 Stimulation

Keywords

  • ExoTMS
  • EXOMIND
  • EEG
03

In context

Lead sponsor

BTL Industries Ltd. is the lead sponsor of 71 studies on the registry; 4 are open to participants now.

Of its 34 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age > 19 years
  • Ability to determine the motor threshold of the participant.
  • Willingness to maintain on pre-study psychotherapeutic regime, and prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry.
  • Willingness to comply with study instructions and to return to the clinic for the required visits
  • Willingness to undergo EEG examination and proceed with the instructions from the study staff during the measurement
  • Women of child-bearing potential are required to use birth control measures during the whole duration of the study

Exclusion criteria

Exclusion Criteria:

  • electronic implants (Implanted stimulator devices in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.),
  • metallic, ferromagnetic or other magnetic-sensitive implants/objects in or near the head*,
  • application in the heart area,
  • persons with a tendency to seizure (hypotonic, epileptic),
  • ongoing anticoagulation therapy,
  • ongoing severe or life-threatening condition,
  • ongoing renal dialysis therapy or decompensated** renal insufficiency,
  • decompensated* hemorrhagic conditions, blood coagulation disorders, cardiovascular diseases,
  • malignant or benign tumour (within 30 cm of the treatment coil),
  • fever,
  • application over or in the near proximity (within 30 cm of the treatment coil) of tattoos with metallic ink
  • pregnancy or nursing
  • suicidal tendencies or recent attempt to commit suicide,
  • concurrent use of electroconvulsive therapy or vagus nerve stimulation,
  • ongoing or recent changes (less than 60 days) in intake doses of any pharmaceutical - products, standalone or in combination, that might lower the threshold of seizure potential,
  • ongoing withdrawal conditions from any dependence substance or medication associated with altered seizure risk history,
  • a psychotic disorder, including schizoaffective disorder, bipolar disease, or major depression with psychotic features,
  • history of primary or secondary tumors in CNS, cerebral aneurysm,
  • history of increased intracranial pressure or head trauma with loss of consciousness.
  • any medication that may alter EEG report (such as benzodiazepines, barbiturates, carbamazepine, valproate, phenothiazines, clozapine, tricyclic antidepressants, lithium, etc.), any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study

    • rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - standard amalgam dental fillings, single post dental implants, and dental bridge work. When these objects are present monitor the patient during therapy and have the patient notify the operator of warming or other sensation; cease rTMS treatment in event of warming sensation) or within 30 cm of the treatment coil. (Examples include implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewellery, and hair barrettes) **This term applies to patients with a documented medical history of a decompensated health condition requiring medical treatment and/or medication, yet has not received such treatment and/or medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment with EXOMIND (BTL-699-2)

    Transcranial magnetic stimulation with the EXOMIND (BTL-699-2) device

    Device: Treatment with EXOMIND (BTL-699-2)

Interventions

  • DeviceTreatment with EXOMIND (BTL-699-2)

    Transcranial magnetic stimulation with the EXOMIND (BTL-699-2) device will be delivered across various stimulation locations. The intensity will be carefully adjusted based on subject feedback, but it should not exceed 70% of the motor threshold.

    Also known as: EXOMIND (BTL-699-2) with ExoTMS

06

What researchers measure

Primary outcomes

  1. Assessment of Eletrical Reactivity using EEG

    The primary outcome is the comparison of changes in EEG power spectral density (PSD) within specific regions for each stimulation location, as well as a comparison of these results between different stimulation locations. These analyses will be performed across all measured participants. EEG measurement will be performed after the stimulation of each location.

    Time frame: 12 months

Secondary outcomes

  1. Assessment of Therapy Comfort

    Therapy Comfort Questionnaire will be used for evaluating the comfort during the treatment sessions. The Therapy Comfort questionnaire will be administered after the stimulation of each location. Therapy Comfort questionnaire consists of the question "I found the treatment comfortable", to which responses are based on a 5-point Likert scale (1 = "strongly disagree", and 5 = "strongly agree"). A higher score for the statement "I found the treatment comfortable" indicate higher therapy comfort.

    Time frame: 12 months

  2. Assessment of Pain During Therapy

    The Therapy Comfort Questionnaire will be used to evaluate pain experienced during the treatment session. It will be administered after the stimulation of each location. The questionnaire includes a 10-point Numeric Analog Scale for pain (0 = no pain, 10 = worst possible pain). Lower scores on the Numeric Analog Scale indicate lower levels of pain.

    Time frame: 12 months

  3. Incidence of Treatment-related Adverse Events

    Monitoring of adverse reactions and side effects will be performed to identify side effects and adverse events associated with the treatment using the BTL-699-2 device.

    Time frame: 12 months

07

Study locations

1 site
  • DP Neuro s.r.o.
    Prague, Prague 162 00, Czechia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07179224
Lead sponsor
BTL Industries Ltd.
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Sep 17, 2025
Primary completion
Oct 29, 2025
Completion
Oct 29, 2025
Last update
Mar 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion